On the regulation and activation of JAK2: A novel hypothetical model

Molecular Cancer Research

Volumn 11, Issue 8, 2013, Pages 811-814

  Lee, Tai Sung ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

DIMERIZATION; HYPOTHESIS; INHIBITION KINETICS; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; JANUS KINASE 2; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84882764015     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0555     Document Type: Review

References (27)

1. Stark GR, Darnell J, James E. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
2. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008;59:213-22.
3. Haan C, Ungureanu D, Pekkala T, Silvennoinen O, Haan S. Regulation of JAKs: insights gleaned from the functional protein domains. In: Jak-Stat signaling: from basics to disease. Decker T, Müller M, editors. Veinna, Austria: Springer; 2012. p. 5-25.
4. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277:47954-63.
5. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20: 3387-95.
6. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-Terminal domains reveals a mechanism for autoregulation. Protein Eng 2001;14:27-37.
7. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105: 4187-90.
8. Lee T-S, Ma W, Zhang X, Giles F, Kantarjian H, Albitar M. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer 2009; 115:1692-700.
9. Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS ONE 2010;5:e11157.
10. Gnanasambandan K, Magis A, Sayeski PP. The constitutive activation of Jak2-V617F is mediated by a p stacking mechanism involving phenylalanines 595 and 617. Biochemistry 2010;49:9972-84.
11. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011;18:971-6.
12. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010;6: 515-25.
13. Zhao L,MaY, Seemann J, shen Huang LJ. Aregulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F). Biochem J 2010; 426:91-8.
14. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 2001;7:377-85.
15. Lu X, Huang LJ-S, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008;283:5258-66.
16. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of theMycand Pim proto-oncogenes. Blood 2008;111:3751-9.
17. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006;108:2435-7.
18. Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, et al. Jak1 has a dominant role over Jak3 in signal transduction through gccontaining cytokine receptors. Chem Biol 2011;18:314-23.
19. Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem 2006;281:7002-11.
20. Constantinescu SN. Mechanism of erythropoietin receptor activation. In: erythropoietins, erythropoietic factors, and erythropoiesis. 2nd ed. Elliott SG, Foote MA, Molineux G, editors. Birkhäuser Basel; 2009. p. 175-96.
21. RemyI, Wilson IA, MichnickSW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999;283:990-3.
22. Kundrapu K, Colenberg L, Duhe RJ. Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. Cell Biochem Biophys 2008;52:103-12.
23. Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, et al. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol 2010;150: 334-44.
24. Lee T-S, Ma W, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. BMC Struct Biol 2009;9:58.
25. Boulanger MJ, Bankovich AJ, Kortemme T, Baker D, Garcia KC. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell 2003;12: 577-89.
26. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011;146:621-32.
27. Gnanasambandan K, Sayeski PP. A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Curr Med Chem 2011;18:4659-73.